

EDITORIAL EXPRESSION OF CONCERN

Open Access



Editorial Expression of Concern: Comparative effectiveness of β -lactam versus vancomycin empiric therapy in patients with methicillin-susceptible *Staphylococcus aureus* (MSSA) bacteremia

Davie Wong^{1*}, Titus Wong^{2,3}, Marc Romney^{2,4} and Victor Leung^{2,4}

Expression of Concern:

Ann Clin Microbiol Antimicrob (2016) 15:27

<https://doi.org/10.1186/s12941-016-0143-3>

The Editors in Chief are issuing this Expression of Concern to alert readers to a number of issues with respect to this article [1].

After publication of this article [1], it has come to the attention of the Editors that there is significant text overlap with [2], although both articles present different conclusions. A subsequent investigation has found that article [2] presents research on an increased group of patients performed solely by the first author, Davie Wong and published in parallel with [1]. Authorship of [2] has now been corrected.¹

Article [1] is a comparison of cloxacillin/cefazolin vs vancomycin in the empiric treatment of MSSA bacteremia, whereas article [2] presents a comparison of beta-lactams (including cloxacillin/cefazolin, ceftriaxone, piptazo, etc.) vs vancomycin. The difference in the conclusions with article [2] may be due to the additional patient data added to study [2]. The institution where this research was carried out has been unable to confirm this.

The original article can be found online at <https://doi.org/10.1186/s12941-016-0143-3>.

*Correspondence: davie1985@hotmail.com

¹ PGY-V Infectious Diseases Residency Training Program, Vancouver General Hospital, University of British Columbia, D 452 Heather Pavilion, 2733 Heather Street, Vancouver, BC V5Z 1M9, Canada
Full list of author information is available at the end of the article

Therefore the Editor advises that readers interpret the data presented with caution.

To further clarify, in article [1] the "Methods" section under "Patients" subsection, the line that reads "The β -lactam group received one or more of cloxacillin, cefazolin, β -lactam/ β -lactamase inhibitor combination, a third generation cephalosporin or a carbapenem, with or without vancomycin" should read "The β -lactam group received either empiric cloxacillin or cefazolin, with or without vancomycin" to indicate that receipt of cloxacillin or cefazolin is a strict inclusion criterion.

Davie Wong, Titus Wong, and Victor Leung agree to this Editorial Expression of concern. Marc Romney did not respond to the correspondence regarding this Editorial Expression of concern.

Author details

¹ PGY-V Infectious Diseases Residency Training Program, Vancouver General Hospital, University of British Columbia, D 452 Heather Pavilion, 2733 Heather Street, Vancouver, BC V5Z 1M9, Canada. ² Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. ³ Medical Microbiology Laboratory, Division of Medical Microbiology and Infection Control, Vancouver General Hospital, JPPN1, 899 W 12th Ave., Vancouver, BC V5Z 1M9, Canada. ⁴ Medical Microbiology Laboratory, Division of Medical Microbiology, St. Paul's Hospital, 1081 Burrard St., Vancouver, BC V6Z 1Y6, Canada.

¹ Erratum to: Wong D. Comparison of outcomes in patients with methicillin-susceptible *Staphylococcus aureus* (MSSA) bacteremia who are treated with β -lactam vs vancomycin empiric therapy: a retrospective cohort study. *BMC Infect Dis*.



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Received: 21 October 2020 Accepted: 21 October 2020
Published online: 17 November 2020

References

1. Wong D, Wong T, Romney M, Leung V. Comparative effectiveness of β -lactam versus vancomycin empiric therapy in patients with methicillin-susceptible *Staphylococcus aureus* (MSSA) bacteremia. *Ann Clin Microbiol Antimicrob*. 2016;15:27. <https://doi.org/10.1186/s12941-016-0143-3>
2. Wong D, Wong T, Romney M, Leung V. Comparison of outcomes in patients with methicillin-susceptible *Staphylococcus aureus* (MSSA) bacteremia who are treated with β -lactam vs vancomycin empiric therapy: a retrospective cohort study. *BMC Infect Dis*. 2016;16:224.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.